一个多重的,主要的编辑框架,用于在规模上识别药物耐药性变体
Florence M C Abadie1, Chase C Suiter2, Nahum T Smith3
1Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA; Seattle Hub for Synthetic Biology, Seattle, WA 98109, USA.
Cell genomics
|February 21, 2026
概括
通过安装和测试整个基因组的众多点突变,Prime-SGE使大规模的功能基因组学成为可能. 这种基于CRISPR的方法使用主要编辑指南RNA测序来评估突变效应,推进药物耐药性选.
科学领域:
- 分子生物学分子生物学
- 基因组学就是基因组学.
- 生物技术是生物技术.
背景情况:
- 基于CRISPR的基因组编辑先进的功能基因组学,允许同时测试成千上万的干扰.
- 和基因组编辑 (SGE) 方法通常集中在每个实验中的一个基因组区域.
研究的目的:
- 开发一种基于CRISPR的新框架,即prime-SGE,用于安装和测试全基因组特定点突变库.
- 通过对主要编辑指导RNAs (pegRNAs) 的测序来实现对众多点突变的功能评估.
主要方法:
- 开发了prime-SGE,这是一个基于prime编辑的系统,用于生成和测试点突变库.
- 在两个细胞系中应用了prime-SGE来选八种瘤基因中的数千个点突变.
- 评估点突变赋予对氨酸激酶抑制剂耐药性的能力.
主要成果:
- 成功地应用了prime-SGE来测试八种瘤基因中的数千个点突变.
- 证明了prime-SGE在识别赋予对氨酸激酶抑制剂耐药性的突变中的有用性.
- 展示了pegRNA测序的可行性,用于对点突变的功能评估.
结论:
- 普莱姆-SGE为整个基因组的点突变的大规模积极选择屏幕提供了一种有效的策略.
- 这种方法,加上主要编辑的进步,扩大了功能基因组学屏幕的范围.
- 为发现与耐药性相关的基因型-表型关系开辟了新的途径.
相关概念视频
01:27Principles of Pharmacogenetics: Types of Genetic Variants
29
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
29
01:29Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
01:27Pharmacogenetics of Drug Metabolism: Overview
31
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
31
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
24
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
24
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
27
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27